PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Greenphire, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

N30 Pharma Selects Greenphire's Global Payment Technology Platforms - N30 Pharmaceuticals has selected Greenphire's global payment technology platforms, eClinicalGPS and ClinCard to streamline payments to investigators & subjects throughout its Phase 1a/2b Cystic Fibrosis study commenced in March - Greenphire.com
N30 Pharma Selects Greenphire's Global Payment Technology Platforms

 

NewswireToday - /newswire/ - Orlando, FL, United States, 2013/04/17 - N30 Pharmaceuticals has selected Greenphire's global payment technology platforms, eClinicalGPS and ClinCard to streamline payments to investigators & subjects throughout its Phase 1a/2b Cystic Fibrosis study commenced in March - Greenphire.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The payment technology platforms will ensure that clinical trial payments from sponsor to site and from site to subjects are compliant with relevant regulations, including the Sunshine Act.

N30 Pharma will use the eClinicalGPS platform to automate payments to investigative sites involved in the trial.

The company will use the ClinCard platform to reimburse subjects and to arrange subject travel, thereby reducing costs and administrative complexities associated with the trial.

N30 Pharma CFO Tom Sokolowski said,"Using Greenphire's systems will ensure that our staff and investigators can focus entirely on the scientific and patient-centric elements of the study while remaining confident that payments are accurate, quick, and fully accounted for."

Greenphire CEO and Co-Founder Sam Whitaker said that the company is looking forward to collaborate with N30 Pharma on its first clinical trial in cystic fibrosis which it hopes will eventually result in new, effective treatments for the disease.

"By using Greenphire's payment platforms to manage the payment and subject travel aspects of the trial, N30 Pharma can reduce costs and risk, remain compliant with relevant regulations, and spend less time managing the logistical aspects of the study," Whitaker added.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Greenphire, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


N30 Pharma Selects Greenphire's Global Payment Technology Platforms

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Greenphire |
Publisher Contact: Press Office - Greenphire.com 
215-609-4378 / 215-609-4640 corporate[.]greenphire.com / sales[.]greenphire.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Greenphire, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Greenphire, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Al Rowaad Advocates & Legal Consultants

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)